Wall Street brokerages expect Bristol-Myers Squibb Co (NYSE:BMY) to announce earnings per share of $0.86 for the current quarter, according to Zacks. Three analysts have made estimates for Bristol-Myers Squibb’s earnings. The highest EPS estimate is $0.96 and the lowest is $0.74. Bristol-Myers Squibb reported earnings per share of $0.84 during the same quarter last year, which would suggest a positive year over year growth rate of 2.4%. The business is expected to issue its next quarterly earnings results before the market opens on Thursday, April 26th.
On average, analysts expect that Bristol-Myers Squibb will report full-year earnings of $3.20 per share for the current financial year, with EPS estimates ranging from $3.10 to $3.28. For the next year, analysts expect that the business will report earnings of $3.77 per share, with EPS estimates ranging from $3.26 to $4.06. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Bristol-Myers Squibb.
Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. The company had revenue of $5.45 billion for the quarter, compared to analyst estimates of $5.35 billion. During the same quarter in the prior year, the business posted $0.63 EPS. The firm’s revenue was up 3.9% compared to the same quarter last year.
BMY has been the topic of a number of analyst reports. Vetr lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 target price on the stock. in a report on Tuesday, January 16th. Citigroup set a $72.00 target price on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a report on Tuesday, December 5th. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Friday, January 19th. Credit Suisse Group set a $62.00 target price on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Monday, January 22nd. Finally, BMO Capital Markets set a $49.00 target price on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a report on Monday, December 11th. Three investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $66.30.
Bristol-Myers Squibb (NYSE:BMY) traded down $0.05 on Monday, hitting $66.63. 4,859,343 shares of the company were exchanged, compared to its average volume of 7,852,710. The company has a quick ratio of 1.43, a current ratio of 1.55 and a debt-to-equity ratio of 0.59. Bristol-Myers Squibb has a 12 month low of $51.56 and a 12 month high of $70.05. The firm has a market cap of $108,780.00, a price-to-earnings ratio of 28.23, a PEG ratio of 2.05 and a beta of 0.98.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 1st. Investors of record on Friday, April 6th will be issued a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 2.40%. The ex-dividend date of this dividend is Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 67.80%.
In other Bristol-Myers Squibb news, Director Theodore R. Samuels II acquired 4,000 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The stock was bought at an average cost of $62.30 per share, with a total value of $249,200.00. Following the acquisition, the director now owns 22,000 shares in the company, valued at $1,370,600. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.23% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Delphi Private Advisors LLC purchased a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at $108,000. Massey Quick Simon & CO. LLC raised its position in shares of Bristol-Myers Squibb by 523.5% during the 3rd quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 1,492 shares in the last quarter. Horan Capital Advisors LLC. purchased a new stake in shares of Bristol-Myers Squibb during the 3rd quarter valued at $122,000. NuWave Investment Management LLC purchased a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at $119,000. Finally, Atlantic Trust LLC purchased a new stake in shares of Bristol-Myers Squibb during the 2nd quarter valued at $111,000. 71.55% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This story was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at https://www.dispatchtribunal.com/2018/04/07/bristol-myers-squibb-co-bmy-expected-to-post-earnings-of-0-86-per-share.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Get a free copy of the Zacks research report on Bristol-Myers Squibb (BMY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.